Meeting
2018 ASCO Annual Meeting
COTI-2, a potent orally available small molecule targeting mutant p53, with promising efficacy as monotherapy and combination treatment in preclinical tumor models.
Authors
Richard T Ho
Cotinga Pharmaceuticals, Boston, MA
Richard T Ho , Kowthar Y Salim , Antje Lindemann , Ameeta A Patel , Hideaki Takahashi , Li Wang , Mei Zhao , Steven J. Frank , Jeffrey Myers , Abdullah A Osman , Christian Lynam , Alison D Silva
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 36, 2018 (suppl; abstr 6040)
DOI
10.1200/JCO.2018.36.15_suppl.6040
Abstract #
6040
Poster Bd #
28
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors.
First Author: Charu Aggarwal
Poster
2023 ASCO Annual Meeting
Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study.
First Author: Maria Pia Morelli
Poster
2011 ASCO Annual Meeting
Evaluation of p53 mutation as a predictive biomarker for outcome to chemotherapy in ovarian cancer.
First Author: A. H. Calvert
Poster
2024 ASCO Annual Meeting
Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma.
First Author: Susanna Varkey Ulahannan